Fresenius SE KGaAXSWX:FRE 71 ROE % is 8.84% as of Mar. 2026, which is 13% below its 10-year median of 10.12. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF32.85 (Fairly Valued). The stock has 5 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Fresenius SE KGaA ranks better than 55.89% on this metric.
The historical rank and industry rank for Fresenius SE KGaA's ROE % or its related term are showing as below:
XSWX:FRE'
s ROE % Range Over the Past 10 Years
Min: -3.01 Med: 10.12 Max: 13.94
Current: 7.72
During the past 13 years, Fresenius SE KGaA's highest ROE % was 13.94%. The lowest was -3.01%. And the median was 10.12%.
XSWX:FRE's ROE % is ranked better than 55.89% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs XSWX:FRE: 7.72
Fresenius SE KGaA (XSWX:FRE) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Fresenius SE KGaA ROE % Related Terms
Fresenius SE KGaA ROE % Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Fresenius SE KGaA's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's ROE % distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Fresenius SE KGaA (XSWX:FRE) has a ROE % of 8.84% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Fresenius SE KGaA and its competitors. This is 13% below median its historical median of 10.12. According to the industry distribution chart, Fresenius SE KGaA ranks #277 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 44.1%.
Is Fresenius SE KGaA's ROE % too high?
Fresenius SE KGaA's current ROE % of 8.84% is 13% below median its 10-year median of 10.12. The Healthcare Providers & Services industry median ROE % is 5.72. Fresenius SE KGaA's value of 8.84% is 54.5% above this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #277 out of 628 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #277 out of 628 companies for ROE %. This puts Fresenius SE KGaA in the upper half of its industry. The industry median ROE % is 5.72. Fresenius SE KGaA's value of 8.84% is 54.5% above this benchmark. While the company's 10-year median is 10.12 vs. the industry median of 5.72, Fresenius SE KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current ROE % of 8.84% is 54.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current ROE % is 8.84%, which is 13% below median its own 10-year median of 10.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF32.85, compared to a current price of CHF35.86 — trading 9.2% above its estimated fair value. The current ROE % is 8.84%, which is 13% below median its 10-year median of 10.12 and 54.5% above the Healthcare Providers & Services industry median of 5.72. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current ROE % is 8.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF35.86 is trading 9.2% above its estimated GF Value™ of CHF32.85.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
ROE %: 8.84% (13% below median its 10-year median of 10.12)
GF Value™: CHF32.85 vs. price of CHF35.86 (9.2% above fair value)
Industry Position: 54.5% above the Healthcare Providers & Services median (#277 of 628)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
